Bayer Articles
Bayer 4th-qtr 2010 revenues up 14.5%, beating expectations, but forecasts group sales growth of 4%-6% for 2011
1 March 2011
Regeneron files BLA for VEGF Trap-Eye treatment with US FDA
23 February 2011
Bayer sets up marketing JV deal with India’s Zydus Cadila to strengthen pharma business in India
31 January 2011
Bayer and Regeneron start Ph III trial to extend ophthalmology R&D program for VEGF Trap-Eye in Asia
19 January 2011
European Commission launches second monitoring purge of patent settlements in pharma sector
18 January 2011
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
Bayer files for EU approval of anticoagulant rivaroxaban for stroke prevention; updates on US filing
6 January 2011
Bayer says it has well-stocked product pipeline, spending more than $4 billion on R&D
9 December 2010
Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib
22 November 2010
Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis
22 November 2010
Bayer joins ranks of European drugmakers shedding jobs, and slashing costs; AstraZeneca confirms viewing Astra Tech options
19 November 2010
Landmark double-blind ROCKET AF study shows Bayer/J&J’s Xarelto is better than warfarin
16 November 2010
New Zealand’s PHARMAC enters deal with InterPharma for seven cancer drugs and with Bayer over Xarelto, Avelox and Copaxone
10 November 2010
Bayer aims to raise its profile, focusing on umbrella brand and dropping Schering name; pays milestone in Micromet deal
9 November 2010
Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest
18 October 2010
Bayer buys rights to “female Viagra” for C$330 million; Johnson & Johnson proceeds with $2.42 billion bid for Crucell
6 October 2010
Bayer Looking for another major acquisition?
29 September 2010
US FDA approves Bayer’s Beyaz, a combination contraceptive with folate, and Allergan’s Ozurdex
26 September 2010
US FDA advisory backs Boehringer Ingelheim’s Pradaxa, putting firm ahead in the race to get new blood thinner on US market
21 September 2010
US FDA briefs: fast-track for Zeltia’s Zentylor; OK for Baxter’s Protopam; warning on gadolinium-based contrast agents
13 September 2010
Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer’s apixaban and Bayer/J&J’s rivaroxaban
1 September 2010
Bayer unit gets rights to KYTHERA’s adipolytic dermatology agent in up to $373 million deal; BTG to regain product rights from Nycomed
31 August 2010
Bayer in deal with UK’s cancer group to evaluate peptide for gynecological and cancer applications
25 August 2010
Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis
5 August 2010
Multinational drugmakers’ sales will represent 92% of Mexico's NSCLC cancer drug Market in 2014
1 August 2010
Bayer’s 2nd-qtr 2010 profits dip 1.3% on charges and write down, despite 14.6% revenue hike
30 July 2010
Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019
13 July 2010
First cannabis-derived medicine comes to market, but there are a few other hurdles to surmount
24 June 2010
Bayer signs mega-million-dollar deal with OncoMed to develop anti-cancer stem cell therapeutics
18 June 2010
US FDA approves GlaxoSmithKline’s Jalyn for symptomatic BPH; fast tracks Genzyme’s MS drug alemtuzumab
15 June 2010
Bayer/Onyx’s Nexavar disappoints as first-line advanced NSCLC therapy, failing to meet goals in Ph III study
14 June 2010
USA’s FTC files amicus brief in support of rehearing of ciprofloxacin "pay-for-delay" case
27 May 2010
Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer’s Nexavar
26 April 2010
Bayer taps ex-Novartis COO as new head of health care unit; pays milestone to Micromet in antibody collaboration
22 April 2010
Novel oral anticoagulants will drive venous thromboembolism market to nearly double by 2018
1 April 2010
Prometheus and Bayer cooperate on accelerating oncology drug development, in deal with up to $160 million
18 March 2010
Rarer Cancer Forum pleads with UK’s NICE to fund Bayer’s Nexavar
25 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Bayer says Ph II BAY79-4980 recombinant Factor VIII trial will not meet primary endpoint
25 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
New state pharma company - ENFARMA - created in Ecuador
4 January 2010
Bayer returns most rights to Recothrom to ZymoGenetics
22 December 2009
HRA Pharma expands to Spain and launches ellaOne
21 December 2009
Bayer Schering Pharma withdraws its MAA for Recothrom in Europe
16 December 2009
Atrial fibrillation drug market to grow more than sevenfold, to $6.1 billion in 2018
16 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
EU achieves political breakthrough on an enhanced patent system
8 December 2009
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
Venezuela to examine all pharma patents?
3 December 2009
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
Bayer Schering collaborates with Micromet on novel approach to cancer therapy in up to $429 million deal
2 December 2009
Regulatory approval briefs: Betaferon in China; new use for Lilly’s Cymbalta in USA; update on telavancin
1 December 2009
Venezuela invalidates two Bayer moxifloxacin patents
30 November 2009
EU Commission and pharma industry launch second call for research proposal towards more efficient drug development methods
30 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
UK’s NICE again rejects Bayer’s Nexavar for advanced liver cancer, but company can, and will, appeal
19 November 2009
MEPs and EU pharma industry debate commitment to deliver 21st Century health care systems in times of crisis
5 November 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Animal research deserves defending
22 October 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
Bayer’s regorafenib shows promise in renal cancer, may fuel Onyx dispute
22 September 2009
Arthur Higgins to quit as CEO of Bayer Healthcare; Marijin Dekkers to be Bayer group CEO
16 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
Innovative medicines initiative: putting Europe at the forefront of biopharmaceutical innovation
15 September 2009
GW reveals strong Sativex data in multiple sclerosis
14 September 2009
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
